Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

Plain-language guide to PMID 24395288 (2014): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 275 participants.

Key Facts

PMID: 24395288
Journal: Pediatric blood & cancer
Year: 2014
Study type: Randomized Controlled Trial
Authors: Kaste SC et al. (13 authors)
DOI: 10.1002/pbc.24882

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Linear regression models were employed to identify the baseline risk factors for low LS-BMD and to compare LS-BMD outcomes.

Why It Was Studied

The primary outcome was change in LS-BMD assessed by quantitative computerized tomography (QCT) at 24 months.

Who Took Part

The abstract describes 275 participants taking part.

PubMed indexes the participants as infants, young children, children, teenagers, young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

The primary outcome was change in LS-BMD assessed by quantitative computerized tomography (QCT) at 24 months.

Topics PubMed links to this paper include Bone Density, Calcium, Dietary, Cholecalciferol, Counseling, Dietary Supplements, Lumbar Vertebrae and Nutrition Therapy.

Author keywords: ALL, childhood cancer survivor, controlled trial and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 275 participants.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Pediatric blood & cancer), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.